Skip to main content

Table 2 Gene expression signature for GC-sensitivity among sensitive and Dex-resistant-restored-to-sensitive leukemias

From: Gene expression profiling of leukemic cells and primary thymocytes predicts a signature for apoptotic sensitivity to glucocorticoids

GC-response

 

Sen.

Sen.

Sen.

Sen.

Sen.

Sen.

Sen.

Resen.

Res.

Patient-derived line

 

Ped.

Ped.

Ped.

Adult

Ped.

Ped.

Ped.

Ped.

Ped.

Cell lineage

 

T-cell

T-cell

T-cell

B-cell

B-cell

Myeloid

T-cell

T-cell

T-cell

Sub-type of leukemia

 

ALL

ALL

ALL

ALL

ALL

AML

ALL

ALL

ALL

Name

Description

C7–14 Dx

C7–14 Z

C1–6 Dx

RS4 Dx

SUP Dx

Kas Dx

C1–15 Z

C1–15 Dx+F

C1–15 Dx

AK2

adenylate kinase 2

-1.4

-1.7

-1.6

-1.4

-2.2

-3.3

-1.6

-1.4

*

BCL2L11

BCL2-like 11 (apoptosis facilitator)

3.1

14.5

5.9

1.2

3.1

5.1

1.3

1.8

*

BTG1

B-cell translocation gene 1, anti-proliferative

9.3

9.1

4.4

1.2

3.9

8.8

3.3

1.7

1.9

CD53

CD53 antigen

3.1

3.4

3.2

1.4

3.1

7.2

1.5

1.8

1.4

CDC6

CDC6 cell division cycle 6 homolog (S. cerevisiae)

-1.3

-1.2

-1.5

-1.7

-2.9

-4.7

-1.3

-1.3

-1.3

DDIT4

DNA-damage-inducible transcript 4

4.4

3.4

2.5

5.5

4.6

22.4

1.2

4.4

1.5

DSCR1

Down syndrome critical region gene 1

5.0

8.2

4.8

1.5

7.7

7.9

1.4

1.6

*

EIF3S9

eukaryotic translation initiation factor 3, subunit 9 eta

-1.5

-2.2

-1.3

-1.2

-2.0

-2.2

-1.2

-1.2

*

FADS1

fatty acid desaturase 1

-1.5

-4.1

-1.9

-1.5

-1.5

-1.8

-1.9

-1.3

-1.3

FKBP5

FK506 binding protein 5

6.6

11.2

4.4

7.0

21.4

13.7

3.8

2.9

2.8

IDH3A

isocitrate dehydrogenase 3 (NAD+) alpha

-1.5

-1.3

-1.5

-1.6

-1.7

-2.4

-1.2

-1.3

*

MARS

methionine-tRNA synthetase

-1.5

-1.6

-1.5

-1.5

-2.2

-2.2

-1.2

-1.3

*

MEP50

WD repeat domain 77

-1.7

-1.4

-1.8

-1.8

-1.5

-1.4

-1.5

-1.3

*

MT1X

metallothionein 1×

1.4

2.1

2.2

1.6

1.8

1.7

1.3

1.4

*

NFKBIA

NFκB inhibitor, alpha

3.0

3.4

2.8

1.9

2.5

5.5

1.9

1.5

1.3

OGT

O-linked N-acetylglucosamine (GlcNAc) transferase

1.3

1.7

2.0

2.0

1.3

2.1

1.6

1.3

*

PA2G4

proliferation-associated 2G4, 38 kDa

-1.7

-1.9

-1.7

-1.3

-2.5

-3.5

-1.3

-1.2

*

PARD3

par-3 partitioning defective 3 homolog (C. elegans)

1.6

1.7

1.4

2.5

1.5

3.0

1.3

1.4

*

PRG1

proteoglycan 1, secretory granule

2.6

4.5

3.2

2.7

1.5

2.7

1.2

1.9

1.6

RAPGEF2

Rap guanine nucleotide exchange factor (GEF) 2

1.7

1.7

1.4

1.8

2.0

4.2

1.3

1.3

*

RBMS1

RNA binding motif, single stranded interacting protein 1

1.4

2.0

1.7

3.0

4.3

2.3

1.6

1.5

1.6

SCARB1

scavenger receptor class B, member 1

-1.7

-2.2

-1.2

-1.4

-4.9

-33.3

-1.5

-1.2

-1.3

TFPI

tissue factor pathway inhibitor

3.1

5.4

1.9

4.9

9.6

24.6

2.0

1.8

1.7

TSC22D3

TSC22 domain family, member 3

33.1

74.0

20.4

5.2

17.5

20.0

7.4

14.0

5.0

TXNIP

thioredoxin interacting protein

2.8

3.4

3.7

10.0

7.7

2.1

1.4

2.0

1.2

YAF2

YY1 associated factor 2

1.8

2.4

1.6

1.7

1.9

5.8

1.7

1.3

1.6

ZNF259

zinc finger protein 259

-1.4

-1.5

-1.8

-1.2

-1.3

-1.6

-1.3

-1.2

*

  1. The 122 genes obtained from comparison of both pediatric (Ped.) and adult GC-sensitive (Sen.) leukemias (see Additional file 2) were compared to Dex-resistant, CVZ-sensitive CEM-C1–15 CVZ (C1–15 Z), and resistant-restored-to-sensitive (Resen.) CEM-C1–15 Dex plus FSK (C1–15 Dx+F) regulated transcripts. These comparisons resulted in 27 genes regulated in the same sense among all naturally GC-sensitive and resistant-restored-to-sensitive human leukemias. This list was subsequently compared to Dex-treated resistant (Res.) CEM-C1–15 cells (C1–15 Dx). Bold type indicates statistically significant regulation p ≤ 0.05 between means of vehicle vs. GC-treated. Symbol, asterisk = gene "absent" by selection criteria.
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us